Estradiol Fluctuation, Sensitivity to Stress, and Depressive Symptoms in the Menopause Transition: A Pilot Study
- PMID: 31244722
- PMCID: PMC6581734
- DOI: 10.3389/fpsyg.2019.01319
Estradiol Fluctuation, Sensitivity to Stress, and Depressive Symptoms in the Menopause Transition: A Pilot Study
Abstract
The menopause transition is associated with an increased risk of depressed mood. Preliminary evidence suggests that increased sensitivity to psychosocial stress, triggered by exaggerated perimenopausal estradiol fluctuation, may play a role. However, accurately quantifying estradiol fluctuation while minimizing participant burden has posed a methodological challenge in the field. The current pilot project aimed to test the feasibility of capturing perimenopausal estradiol fluctuation via 12 weekly measurements of estrone-3-glucuronide (E1G), a urinary metabolite of estradiol, using participant-collected urine samples in 15 euthymic perimenopausal women ages 45-55 years. Furthermore, it aimed to correlate E1G fluctuation (standard deviation across the 12 E1G measurements) with weekly mood and cardiovascular, salivary cortisol, and subjective emotional responses to the Trier Social Stress Test (TSST) at weeks 4, 8, and 12. Protocol acceptability and adherence was high; furthermore, E1G fluctuation was positively associated with anhedonic depressive symptoms and weekly negative affect. E1G fluctuation was also associated with increased heart rate throughout the TSST as well as higher levels of rejection, anger, and sadness. E1G fluctuation was not significantly associated with TSST blood pressure or cortisol levels. This study suggests a feasible method of assessing estradiol fluctuation in the menopause transition and provides support for the hypothesis that perimenopausal estradiol fluctuation increases sensitivity to psychosocial stress and vulnerability to depressed mood.
Keywords: estradiol; estrone-3-glucuronide; menopause transition; perimenopausal depression; trier social stress test.
Figures







Similar articles
-
Mood sensitivity to estradiol predicts depressive symptoms in the menopause transition.Psychol Med. 2021 Jul;51(10):1733-1741. doi: 10.1017/S0033291720000483. Epub 2020 Mar 11. Psychol Med. 2021. PMID: 32156321
-
Testosterone and depressive symptoms during the late menopause transition.Biol Sex Differ. 2021 Jul 30;12(1):44. doi: 10.1186/s13293-021-00388-x. Biol Sex Differ. 2021. PMID: 34330326 Free PMC article.
-
Within-person changes in reproductive hormones and cognition in the menopause transition.Maturitas. 2023 Nov;177:107804. doi: 10.1016/j.maturitas.2023.107804. Epub 2023 Jul 22. Maturitas. 2023. PMID: 37536173
-
The role of estradiol fluctuation in the pathophysiology of perimenopausal depression: A hypothesis paper.Psychoneuroendocrinology. 2021 Nov;133:105418. doi: 10.1016/j.psyneuen.2021.105418. Epub 2021 Sep 13. Psychoneuroendocrinology. 2021. PMID: 34607269 Review.
-
Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model.Am J Psychiatry. 2015 Mar 1;172(3):227-36. doi: 10.1176/appi.ajp.2014.14070918. Epub 2015 Jan 13. Am J Psychiatry. 2015. PMID: 25585035 Free PMC article. Review.
Cited by
-
Complete Resolution of Catatonia Following a Single Intravenous Lorazepam Challenge Test: An Early Intervention in Psychosis Case Report.Psychopharmacol Bull. 2025 Jan 1;55(1):70-75. Psychopharmacol Bull. 2025. PMID: 39744407 No abstract available.
-
How preclinical models of menopause can inform clinical care: A focus on midlife and reciprocal communication between clinical and preclinical science.Curr Opin Endocr Metab Res. 2023 Feb;28:100434. doi: 10.1016/j.coemr.2023.100434. Epub 2023 Jan 13. Curr Opin Endocr Metab Res. 2023. PMID: 39484630 Free PMC article.
-
Sex steroid hormones in depressive disorders as a basis for new potential treatment strategies.Physiol Res. 2022 Dec 31;71(S2):S187-S202. doi: 10.33549/physiolres.935001. Physiol Res. 2022. PMID: 36647907 Free PMC article. Review.
-
Estrogen fluctuations during the menopausal transition are a risk factor for depressive disorders.Pharmacol Rep. 2023 Feb;75(1):32-43. doi: 10.1007/s43440-022-00444-2. Epub 2023 Jan 14. Pharmacol Rep. 2023. PMID: 36639604 Free PMC article. Review.
-
Estradiol and progesterone from pregnancy to postpartum: a longitudinal latent class analysis.Front Glob Womens Health. 2024 Oct 9;5:1428494. doi: 10.3389/fgwh.2024.1428494. eCollection 2024. Front Glob Womens Health. 2024. PMID: 39444825 Free PMC article.
References
-
- American Psychiatric Association (2000). Diagnostic and Statistical Manual of Menstal Disorders. Washington, DC: American Psychiatric Association.
-
- Appelhof B. C., Huyser J., Verweij M., Brouwer J. P., van Dyck R., Fliers E., et al. (2006). Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol. Psychiatry 59 696–701. 10.1016/j.biopsych.2005.09.008 - DOI - PubMed
-
- Avis N. E., McKinlay S. M. (1995). The massachusetts women’s health study: an epidemiologic investigation of the menopause. J. Am. Med. Womens Assoc. (1972) 50 45–49. - PubMed
LinkOut - more resources
Full Text Sources